Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 228,424 | 238,014 | 195,442 | 163,794 | 117,626 |
| Receivables | 617,740 | 514,033 | 472,248 | 430,016 | 364,050 |
| Inventories | 185,695 | 160,660 | 127,892 | 114,956 | 95,833 |
| Other current assets | 72,560 | 56,030 | 48,807 | 81,315 | 45,008 |
| TOTAL | $1,201,131 | $1,021,325 | $897,836 | $826,625 | $656,832 |
| Non-Current Assets | |||||
| PPE Net | 1,124,358 | 1,044,128 | 932,877 | 781,973 | 755,827 |
| Intangibles | 1,875,262 | 1,616,405 | 1,320,076 | 872,777 | 861,808 |
| Other Non-Current Assets | 1,290,080 | 1,010,932 | 705,090 | 448,547 | 437,333 |
| TOTAL | $4,289,700 | $3,671,465 | $2,958,043 | $2,103,297 | $2,054,968 |
| Total Assets | $5,490,831 | $4,692,790 | $3,855,879 | $2,929,922 | $2,711,800 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 50,214 | 38,545 | 31,416 | 30,998 | 27,313 |
| Accounts payable and accrued liabilities | 122,475 | 111,498 | 66,250 | 77,838 | 68,485 |
| Accrued Expenses | 356,643 | 297,735 | 244,137 | 190,824 | 177,941 |
| Other current liabilities | 102,477 | 90,598 | 71,280 | 44,460 | 26,500 |
| TOTAL | $839,751 | $710,181 | $558,222 | $463,504 | $429,593 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,929,571 | 1,849,666 | 1,636,598 | 1,114,105 | 1,207,696 |
| Deferred Revenues | 207,942 | 171,805 | 145,139 | 117,569 | 127,731 |
| Other Non-Current Liabilities | 385,307 | 325,790 | 195,295 | 213,272 | 178,068 |
| TOTAL | $2,532,911 | $2,344,781 | $1,977,879 | $1,419,011 | $1,443,082 |
| Total Liabilities | $3,372,662 | $3,054,962 | $2,536,101 | $1,882,515 | $1,872,675 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 49,776 | 48,960 | 48,226 | 47,429 | 47,373 |
| Common Shares | 498 | 489 | 482 | 875 | 863 |
| Retained earnings | 625,414 | 280,329 | 42,096 | 288,658 | 165,303 |
| Other shareholders' equity | -135,307 | -174,775 | -170,312 | -142,318 | -251,412 |
| TOTAL | $2,118,169 | $1,637,828 | $1,319,778 | $1,047,407 | $839,125 |
| Total Liabilities And Equity | $5,490,831 | $4,692,790 | $3,855,879 | $2,929,922 | $2,711,800 |